Merck & Co., Inc.

Merck & Co., Inc., known also as Merck Sharp & Dohme (MSD) outside the United States and Canada, is a multinational pharmaceutical corporation that researches, develops, manufactures and markets a broad range of human health products. Its portfolio includes prescription medicines for oncology, infectious diseases, cardiology, endocrinology and respiratory conditions, as well as vaccines that prevent illnesses such as human papillomavirus‑related cancers and measles, mumps and rubella. The company also produces animal health products and operates a biologics division that focuses on therapeutic proteins and biosimilars. These offerings are distributed to hospitals, clinics, pharmacies and wholesale channels in markets across North America, Europe, Asia, Africa and Latin America.

The firm maintains a substantial global footprint, with research and development sites, manufacturing plants and commercial offices located in dozens of countries. It employs a diverse workforce that supports its mission to bring innovative therapies to patients worldwide. Merck’s presence in emerging markets is reinforced through partnerships with local health authorities and distribution networks that aim to improve access to essential medicines. Its scale enables the company to conduct large‑scale clinical trials and to respond rapidly to public health needs, as demonstrated during vaccine outreach initiatives.

Merck is distinguished by its leadership in immuno‑oncology, most notably through the development and commercialization of the checkpoint inhibitor pembrolizumab (Keytruda), which has become a cornerstone treatment for multiple cancer types. The organization also has a longstanding reputation in vaccine science, having contributed to the eradication of certain infectious diseases through its immunization programs. Regulatory interactions are a core competency, with the company routinely navigating complex approval processes in the United States, European Union and other jurisdictions to bring new therapies to market. These capabilities are underpinned by a robust pipeline that emphasizes biologics, small‑molecule molecules and novel therapeutic modalities.

Structurally, Merck & Co., Inc. is a publicly traded corporation listed on the New York Stock Exchange under the ticker MRK, with its headquarters situated in Kenilworth, New Jersey, United States. Outside North America, the company operates under the Merck Sharp & Dohme (MSD) brand through a network of subsidiaries and affiliates that manage regional commercial activities. Ownership is dispersed among institutional and individual investors, and the firm maintains a corporate governance framework that includes a board of directors overseeing strategic direction and risk management. This structure supports its ability to allocate resources across global research initiatives while adhering to the regulatory and ethical standards expected of a major pharmaceutical enterprise.